跳至主要内容
临床试验/NCT00166322
NCT00166322已完成不适用

Dopaminergic Neurotransmission in Schizophrenia, Patients at Risk and Healthy Subjects

Ludwig-Maximilians - University of Munich4 个研究点 分布在 1 个国家目标入组 35 人开始时间: 2004年1月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
35
试验地点
4
主要终点
dopamine receptor availability

研究概览

简要总结

This study is an investigation of the dopaminergic neurotransmission in patients with schizophrenia, patients at risk for the development of schizophrenia, and healthy controls using an iodobenzamide-single photon emission computed tomography (IBZM-SPECT) imaging technique under amphetamine challenge.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
主要目的
Diagnostic
盲法
None

入排标准

年龄范围
18 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Clinical diagnosis of schizophrenia (currently unmedicated)
  • Subjects at risk for the development of schizophrenia (prodromal symptoms)
  • Healthy subjects
  • Written informed consent

排除标准

  • Neurological or severe somatic disorders
  • Women during pregnancy or lactation
  • Occupational exposition to radiation > 15mSv
  • Medication known to interfere with IBZM
  • Contraindications for the use of amphetamine challenge

结局指标

主要结局

dopamine receptor availability

时间窗: cross-sectional

次要结局

未报告次要终点

研究者

申办方类型
Other

研究点 (4)

Loading locations...

相似试验